Partnering Activity Update. November 6, 2017

Transcription

1 Partnering Activity Update November 6, 2017

2 Recent Partnering Date Product name / code number Indication / MOA Phase (JP / Overseas) Partner 2010 KYPROLIS / Carfilzomib Multiple Myeloma / Proteasome inhibitor Amgen, USA (Onyx, USA) 2011 Ivabradine / Chronic Heart Failure / If channel blocker III / L Servier, France 2011 PARSABIV / Etelcalcetide Secondary Hyperparathyroidism / Calcium sensing receptor agonist Amgen, USA (KAI, USA) 2011 ORENCIA / Abatacept Rheumatoid Arthritis / T cell activation Inhibitor IV: SC: BMS, USA (co-development & co-marketing) Apr 2013 Opicapone / Symptom Reemergence in Parkinson s disease / COMT inhibitor II / L Bial, Portugal Oct 2013 Metyrosine / Pheochromocytoma / Tyrosine hydroxylase inhibitor I/II / L Valeant, USA Dec 2013 FORXIGA / Dapagliflozin Type 2 Diabetes / SGLT-2 inhibitor AstraZeneca, UK (co-promotion)

3 Recent Partnering Date Product name / code number Indication / MOA Phase (JP / Overseas) Partner May 2016 IT1208 Solid Tumors / Anti-CD4 mab I/ - IDAC Theranostics, Japan (Exclusive evaluation and license negotiation right) Jul 2016 NKR-2 Solid Tumors and Hematological Malignancies / Allogeneic CAR T-cell therapy PC / PC Celyad, Belgium May 2017 Binimetinib / Encorafenib / Binimetinib / Encorafenib / BRAF-mutant melanoma / MEK inhibitor Combination BRAF inhibitor therapy BRAF-mutant melanoma / MEK inhibitor Combination BRAF inhibitor therapy III / Filed - / III Array, USA Aug 2017 SI-613 / Osteoarthritis / Combined drug of hyaluronic acid and NSAID III / - Seikagaku, Japan (co-development & marketing collaboration ) Oct 2017 Selinexor KPT-8602 Solid Tumors and Hematological Malignancies / XPO1 (Exportin 1) inhibitor Solid Tumors and Hematological Malignancies / second generationxpo1 (Exportin 1) inhibitor -/ Ⅲ - / PC Karyopharm, USA

4 Recent Partnering Date Product name / code number Indication / MOA Phase (JP / Overseas) Partner 2011 OPDIVO / Nivolumab Melanoma, NSCLC, RCC, Hodgkin Lymphoma, Head and Neck Cancer, etc. / Anti-PD-1 mab BMS, USA (out-license except JP, KR & TW) May 2013 OPALMON / Limaprost α-cd Lumber Spinal Canal Stenosis / oral PGE1 analogue L/PC Dainippon Sumitomo Pharma, Japan (out-license in China) Jul 2014 OPALMON / Limaprost α-cd Lumber Spinal Canal Stenosis / oral PGE1 analogue L / Filed Meiji Seika Pharma, Japan (out-license in Thailand & Indonesia) Dec 2014 Tirabrutinib / B Cell Lymphoma / Btk inhibitor I/II / II Gilead Sciences, USA (out-license except JP, KR, TW, CN & ASEAN) May 2015 OPALMON / Limaprost α-cd Lumber Spinal Canal Stenosis / oral PGE1 analogue L / - China Chemical & Pharmaceutical, Taiwan (out-license in Taiwan) Mar 2016 etaprost / Glaucoma and Ocular Hypertension / FP/EP3 dual receptor agonist II / II Santen Pharmaceutical, Japan (out-license globally as ophthalmologic topical formulation) OPDIVO / Nivolumab Melanoma, NSCLC, RCC, Hodgkin Lymphoma, H&N Cancer, Gastric Cancer, etc. / Anti-PD-1 mab Jul 2014 YERVOY / Ipilimumab Lirilumab / Urelumab / Relatlimab / BMS / Cabiralizumab / BMS / Melanoma, etc. / Anti-CTLA-4 mab Cancer / Anti-KIR mab Solid Tumors / Anti-CD137 mab Solid Tumors / Anti-LAG3 mab Solid Tumors / Anti-TIGIT mab Solid /Blood cancer / Anti-CSF1R mab Solid /Blood cancer / IDO1 inhibitor I / II I / II I / II I/II / I I / I I / II BMS, USA co-development & co-promotion in JP, KR & TW Launched in Japan

5 Collaboration with BMS for OPDIVO Innovative Immuno-oncology Therapy Start collaboration in May 2005 Expand collaboration in 2011 IP on PD-1 UltiMab Human Antibody Development System Worldwide except N America Medarex BMS Acquisition of Medarex in July 2009 North America JP, KR & TW BMS Worldwide except N America, JP, KR & TW North America

6 Strategic Alliance with BMS in JP, KR & TW To Strengthen Immuno-oncology Portfolio To Accelerate Combination Therapies Co-development Co-promotion BMS Distribution BMS Subsidiary Medical sites Promotion BMS Subsidiary Development cost share Profit/loss allocation Mainly BMS BMS BMS Partly + Equally Partly BMS BMS BMS Mainly Mainly Partly Equally Partly Mainly

7 Collaboration with BMS for ORENCIA Novel Biologic Inhibiting Upstream Inflammation in RA BMS Distribution SC SC IV BMSKK IV Promotion Medical sites SC IV BMSKK BMKK: Bristol-Myers Squibb K. K.

8 Collaboration with AstraZeneca for FORXIGA The First SGLT-2 Inhibitor in the World for Type 2 Diabetes Distribution Promotion Medical sites AZKK AZKK: AstraZeneca K.K.